The organizational realignment and optimization include phasing out programs in influenza, COVID-19, and the Company’s T cell-based viral vector platform, as well as a workforce reduction of approximately 25% or approximately 140 employees.
Vir Biotechnology: Development of antibody VIR-2981 against influenza discontinued